Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Chardan Capital Markets Reiterates Buy Rating on Arrowhead Pharma (ARWR)
-
Eyenovia Inc (EYEN) Prices $1.3M Offering at $0.1076/sh
-
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
-
Forte Biosciences (FBRX) Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
-
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications
-
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio
-
Clear Street Launches Equity Research Group
-
Chardan Capital Markets Downgrades Allurion Technologies (ALUR) to Neutral
-
Form SC 13G NewGenIvf Group Ltd Filed by: CHARDAN CAPITAL MARKETS LLC
-
Form 3 NewGenIvf Group Ltd For: Apr 03 Filed by: CHARDAN CAPITAL MARKETS LLC
-
Ocugen Secures $30 Million in Debt Funding
-
Sonnet BioTherapeutics (SONN) Prices 1.11M Share Offering at $4.50/sh
-
Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules
-
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)
-
Coya Therapeutics Announces Closing of $10.0 Million Private Placement
-
Coya Therapeutics (COYA) Announces 1.38M Share Offering at $7.25/sh
-
Coya Therapeutics Announces $10.0 Million Private Placement
-
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
-
VivoPower (VVPR) to close F-1 offering
-
VivoPower decides to close F-1 offering, after successfully raising $4m in gross proceeds from institutional investors
-
Aspen Neuroscience Chief Financial Officer Kameel Farag to Present at Upcoming Investor Conferences
-
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
-
ARTHEx Biotech Announces Participation in 8th Annual Chardan Genetic Medicines Conference
-
Avidity Biosciences to Participate in Upcoming Investor Conference
-
ReCode Therapeutics to Participate in Upcoming Investor Conferences
-
Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference
-
Atsena Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
-
Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
-
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
-
Coave Therapeutics to Present Novel Data Highlighting the Potential of its ALIGATER™ Platform to Enhance the Targeted Delivery of Genetic Medicines at Upcoming Conferences
-
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference
-
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
-
Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference
-
Spur Therapeutics to Participate in Chardan’s 8th Annual Genetic Medicines Conference
-
Affinia Therapeutics to Participate in Upcoming Investor and Industry Conferences
-
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
-
Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
-
Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference
-
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
-
Chardan Capital Markets Starts CervoMed (CRVO) at Buy
-
Atamyo Therapeutics to Provide Corporate Overviews and Updates on Its Pipeline Progress at 6 Upcoming Conferences in the US and Europe
-
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
-
Korro to Participate in Upcoming Investor Conferences
-
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
-
Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences
-
Capsida Biotherapeutics to Participate in Upcoming Investor and Industry Conferences Highlighting Progress With its Wholly Owned Programs in IND-enabling Studies
-
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
-
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences
-
Senti Bio to Participate in Upcoming Investor Conferences
-
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

